Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.20    -0.11 (-8.40%)
Bid:
1.10
Ask:
1.30
Spread: 0.20 (18.182%)
Market Cap: £10.27m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

Rule 2.9 Announcement - Update

10 Jun 2022 08:29

RNS Number : 4577O
Pires Investments PLC
10 June 2022
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

10 June 2022

Pires Investments Plc

("Pires" or the "Company")

Rule 2.9 Announcement

As previously announced, the Company allotted a total of 649,982 new ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") on 6 June 2022 following the exercise of warrants over 649,982 Ordinary Shares in the Company at an exercise price of 4 pence per warrant.

Following issue of the Ordinary Shares this morning, the number of Ordinary Shares in issue and admitted to trading on AIM will be 161,395,191. This figure of 161,395,191 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Ordinary Shares are relevant securities of Pires Investments plc for the purposes of Rule 8 of The City Code on Takeovers and Mergers (the "Code").

In accordance with Rule 2.9 of the Code, Pires confirms that, as at the date of this announcement, it has 161,395,191 Ordinary Shares of nominal value 0.25 pence each in issue with ISIN GB00BD07SH45. Pires does not hold any securities (including Ordinary Shares) in treasury.

For further information please contact:

Pires Investments plc

Nicholas Lee, Director

 

Tel: +44 (0) 20 3368 8961

 

Nominated Adviser

Cairn Financial Advisers LLP

James Lewis/Liam Murray/Ludovico Lazzaretti

 

 

Tel: +44 (0) 20 7213 0880

Joint Broker

Peterhouse Capital Limited

Duncan Vasey/Lucy Williams

 

 

Tel: +44 (0) 20 7469 0935

Tel: +44 (0) 20 7469 0936

Joint Broker

Tennyson Securities

Peter Krens

 

Tel: +44 (0) 20 3167 7221

 

Financial media and PR

Yellow Jersey

Sarah Hollins/Henry Wilkinson/Annabelle Wills

 

Tel: +44 (0) 20 3004 9512

 

 

Notes to Editors

 

About Pires Investments plc

 

Pires Investments plc (AIM: PIRI) is an investment company providing investors with access to a portfolio of next generation technology businesses with significant growth potential.

 

The Company is building an investment portfolio of high-tech businesses across areas such as Artificial Intelligence, Internet of Things, Cyber Security, Machine Learning, Immersive Technologies and Big Data, which the Board believes demonstrate evidence of traction and the potential for exponential growth, due to increasing global demand for development in these sectors.

 

For further information, visit: https://piresinvestments.com/.

 

Miscellaneous

Cairn Financial Advisers LLP, which is authorised and regulated by the FCA in the UK, is acting as financial adviser and Rule 3 adviser exclusively for Pires and no one else in connection with the matters set out in this announcement and will not be responsible to any person other than Pires for providing the protections afforded to clients of Cairn Financial Advisers LLP, nor for providing advice in relation to the contents of this announcement or any matter referred to herein. Cairn Financial Advisers LLP's responsibilities as Pires' Nominated Adviser under the AIM Rules for Companies and AIM Rules for Nominated Advisers are owed solely to London Stock Exchange and no other person.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTZZGMVNGRGZZG
Date   Source Headline
16th Dec 20247:01 amRNS-ROnline Investor Presentation and Q&A Session
16th Dec 20247:00 amRNSPlacing to raise £400,000
1st Nov 20247:00 amRNSDirector/PDMR Shareholding
29th Oct 20247:00 amRNSBoard Changes
25th Oct 20248:27 amRNSFurther re. Wyld Networks Rights Issue
15th Oct 20247:00 amRNSPlacing to raise £625,000
30th Sep 20245:04 pmRNSTotal Voting Rights
30th Sep 20247:00 amRNSDevice Authority Update
23rd Sep 202411:13 amRNSReplacement: Results of Open Offer
23rd Sep 202411:10 amRNSResult of General Meeting
23rd Sep 20247:00 amRNSResults of Open Offer
5th Sep 20247:00 amRNSOpen Offer and Notice of General Meeting
5th Sep 20247:00 amRNSInterim results for the six months to 30 June 2024
2nd Sep 202410:16 amRNSStatement re Wyld Networks Rights Issue
9th Aug 20247:00 amRNSPartial sale of Device Authority holding
27th Jun 202412:00 pmRNSResult of AGM
31st May 20245:00 pmRNSTotal Voting Rights
30th May 20247:00 amRNSResults for the year ended 31 December 2023
15th May 20247:00 amRNSExercise of Warrants
3rd May 20247:45 amRNSFurther re. Wyld Networks Warrant Exercise Process
30th Apr 20245:00 pmRNSTotal Voting Rights
25th Apr 20247:00 amRNSExercise of warrants held in Wyld Networks
12th Apr 20247:00 amRNSPlacing to raise £420,000
9th Apr 20247:00 amRNSTalking Medicines record revenue bookings in Q1 24
21st Mar 20247:00 amRNSOnline Investor Presentation and Q&A Session
5th Mar 20247:00 amRNSKonektio Administration
7th Feb 20247:00 amRNSDevice Authority Fund Raise
1st Feb 20247:00 amRNSTalking Medicines Fundraise
31st Jan 20245:32 pmRNSTotal Voting Rights
24th Jan 20247:00 amRNSPlacing to raise £400,000
15th Jan 20243:22 pmRNSHolding(s) in Company
28th Dec 20237:00 amRNSCompletion of Tranche One of the DA Fund raise
27th Dec 20237:00 amRNSDevice Authority Fund raise
29th Nov 20237:00 amRNSKonektio update
24th Nov 20237:00 amRNSInvestor Webinar Recording
21st Nov 20237:00 amRNSCompany and Portfolio Update
15th Nov 20237:00 amRNSOnline Investor Presentation and Q&A Session
8th Nov 20237:00 amRNSKonektio update
26th Sep 202312:19 pmRNSResult of GM
31st Aug 20237:00 amRNSNotice of General Meeting
16th Aug 20237:00 amRNSInterim results for the six months to 30 June 2023
10th Aug 20237:00 amRNSBoard and Management Restructuring
4th Aug 20231:33 pmRNSStatement re Share Price Movement
4th Jul 20237:00 amRNSDevice Authority convertible loan note extension
30th Jun 20235:00 pmRNSTotal Voting Rights
29th Jun 202310:09 amRNSResult of AGM and Directorate Change
28th Jun 20237:00 amRNSDevice Authority - Winner of Microsoft Award
12th Jun 202311:35 amRNSFunding facility
31st May 20237:00 amRNSResults for the year ended 31 December 2022
26th May 20237:00 amRNSKonektio Fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.